What happens during a ChondroFiller hip injection

The appointment takes around an hour from start to finish and requires no surgical incision, no theatre admission, and no general anaesthetic — only a local anaesthetic to the skin over the injection site.

Before the needle is placed, the treating consultant reviews pre-treatment MRI images to map the exact size, depth, and location of the cartilage defect on the femoral head. That review determines where the needle must go and how much ChondroFiller is needed; no two hip defects are identical.

With the patient positioned on the couch, a fine needle is advanced under real-time ultrasound guidance through the soft-tissue layers surrounding the hip joint. The ultrasound screen allows the clinician to watch the needle tip continuously as it travels to the joint surface and into the defect pocket.

Once intralesional placement is confirmed, the collagen solution is expressed. At body temperature it self-gels within roughly three to five minutes, forming a structured scaffold inside the defect. The hip is then held under controlled traction for approximately 12–15 minutes while the gel cures and bonds to the surrounding tissue.

Most patients leave the clinic the same day. A period of limited weight-bearing — typically four to six weeks, often with crutches — follows before a gradual return to normal activity.

How the scaffold works — and why placement is everything

ChondroFiller contains no donor cells and no live biological components. Its role is entirely chemotactic — once the collagen matrix gels inside a focal defect, it acts as a three-dimensional template that signals the body to send its own repair cells into the lesion.

That process — known as acellular matrix-induced chondrogenesis — follows a clear biological sequence. Ex vivo work using human osteochondral tissue has confirmed that mesenchymal stem cells and chondrocyte precursors (the body's cartilage-forming progenitor cells) begin migrating into the scaffold within the first two weeks of contact. Over the following three to six months, those recruited cells progressively remodel the collagen matrix into fibrocartilage-like repair tissue while the original scaffold biodegrades around them.

The mechanism is entirely location-dependent. For cell recruitment to begin, the scaffold must physically occupy the discrete defect pocket — a space with defined walls and a subchondral floor that concentrate the chemotactic signal. Gel dispersed into the surrounding joint cavity cannot form that structured template; without an anchor, repair cannot proceed.

A second constraint follows from the scaffold's chemistry. ChondroFiller sets irreversibly on contact with body temperature. Once expressed, mislaid gel cannot be retrieved or repositioned. The needle tip must be confirmed inside the defect before injection begins — not after. This is a biological requirement, not a procedural preference, and it is precisely what makes accurate placement so consequential.

Why the hip makes accurate placement difficult

The femoral head sits several centimetres beneath thick layers of gluteal and hip-flexor musculature, with no bony prominence or surface marker that reliably indicates where a needle tip sits relative to a focal defect. In a more accessible joint such as the knee, surface anatomy can guide approximate placement for injectables that distribute freely across the joint cavity — hyaluronic acid or corticosteroid can reach the synovial lining from almost any intra-articular entry point, and distributing across the joint space is often precisely the aim. The hip offers no equivalent shortcut: the joint surface is inaccessible to visual or tactile confirmation, and there is no reliable external landmark for intralesional needle positioning.

Evidence from orthobiologics practice more broadly — not from a ChondroFiller-specific randomised trial — indicates that up to 30% of intra-articular hip injections performed without imaging guidance fail to achieve intralesional placement. The needle enters the joint, but the injectate lands in the surrounding cavity rather than inside the focal defect pocket. For a non-scaffold product designed to disperse through the joint, this may be clinically acceptable; a corticosteroid or viscosupplement distributed across the wider synovial space can still moderate symptoms. For a scaffold whose mechanism depends entirely on occupying a discrete, walled lesion — as the previous section described — the same misplacement removes any possibility of the repair sequence beginning at all.

Because the gel sets irreversibly on contact (see above), there is no correcting a misplaced injection after the fact. Verification before the collagen solution is expressed is the only viable checkpoint.

How real-time ultrasound solves the placement problem

That MRI review — completed before the appointment — informs two things the scan alone cannot deliver in the room: exactly how many units of scaffold material are required and the precise needle trajectory the defect geometry demands. No standardised, one-size approach is possible; a consultant who has not seen the imaging cannot meaningfully plan either.

What real-time ultrasound then provides is the live confirmation that the MRI cannot. As the needle passes through the deep soft-tissue layers toward the femoral head, the operator follows the tip position directly on screen — frame by frame, not as an inference from surface landmarks. Trajectory can be adjusted in response to what the image shows rather than committed to in advance.

The defining checkpoint is the instant before the collagen solution is released. Ultrasound confirms that the tip has entered the focal defect pocket — not merely the joint cavity — before any gel is expressed. Given that the scaffold sets irreversibly on contact, that confirmation must come at this moment; there is no corrective step once injection begins.

At the Sleaford centre, MSK Doctors' Open MRI scanner is available on-site, so defect mapping and treatment planning can be completed within the same appointment cycle without coordinating imaging across separate facilities.

Taken together, pre-procedure MRI planning and image-guided needle placement address the mechanism behind the off-target rate described in the previous section — replacing spatial assumption with confirmed intralesional placement before the setting process begins.

Who is suitable for ChondroFiller hip injection

Candidacy turns on one anatomical fact: the scaffold needs a focal lesion to template. Cartilage defects with clearly defined borders — often the result of femoroacetabular impingement (FAI), acute trauma, or localised wear — provide the contained geometry the collagen gel requires. Early-to-moderate joint degeneration generally falls within the indicated range, provided the affected area is discrete enough for targeted placement.

The principal contraindication is advanced osteoarthritis. At Tönnis grade 2–3, cartilage loss has become diffuse and widespread; there is no bounded defect pocket for the scaffold to occupy, and a different treatment pathway — potentially joint replacement — is more appropriate for that degree of degeneration.

Between these two poles lies a zone that requires clinical judgement. MRI assessment determines defect size, depth, and location — the same imaging that guides injection planning also confirms whether the lesion geometry is suitable for ChondroFiller at all. At the Sleaford and Grantham centres, MSK Doctors' onMRI AI-assisted analysis supports this defect-characterisation step. A consultant assessment can be arranged directly, without a GP referral, at mskdoctors.com.

Recovery timeline and what the evidence shows

The recovery arc begins where the appointment ends. For most patients, weight-bearing is limited for the first four to six weeks while the newly deposited scaffold integrates with surrounding tissue — a period that coincides with the earliest phase of cell recruitment, which ex vivo work in human osteochondral tissue has confirmed begins within the first fortnight. Meaningful improvement typically builds across the following months as recruited mesenchymal and chondral cells progressively lay down fibrocartilage-like repair tissue and the original collagen matrix biodegrades in parallel. Peak benefit is generally expected at three to six months.

Published hip cohort data provide the clearest guide to what that benefit looks like. Harris Hip Score improvements of approximately 33 points have been reported in hip-specific series, alongside MOCART MRI regeneration scores of 70–87 — a validated imaging measure of repair-tissue fill and integration. Across published series spanning knee, hip, and smaller joints, 70–85% of treated patients achieved meaningful symptom relief. More than 19,000 ChondroFiller cases have now been performed globally, and the reported complaint rate stands at approximately 0.06%.

Those figures merit honest framing. Most hip-specific series are prospective observational cohorts rather than randomised controlled trials, and durability data beyond two to three years remain limited. What the current evidence can reasonably support is that carefully selected patients with focal hip cartilage defects may achieve significant, measurable, medium-term symptomatic improvement — a conclusion grounded in consistent cohort findings and a safety profile established at meaningful clinical scale.